Loading…
Immix Biopharma, Inc. is projected to rise to $13.83 by 2027, a +66% move from its current price of $8.32. IMMX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $7.97 | $8.33 | $8.71 | +0.11% |
| Aug 3 | $7.83 | $8.34 | $8.88 | +0.22% |
| Aug 4 | $7.73 | $8.35 | $9.01 | +0.33% |
| Aug 5 | $7.65 | $8.36 | $9.13 | +0.44% |
| Aug 6 | $7.58 | $8.37 | $9.24 | +0.55% |
| Aug 7 | $7.51 | $8.38 | $9.33 | +0.66% |
| Aug 8 | $7.46 | $8.38 | $9.43 | +0.77% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.46 | $8.38 | $9.43 | +0.77% |
| Week 2 | $7.16 | $8.45 | $9.97 | +1.55% |
| Week 3 | $6.95 | $8.51 | $10.43 | +2.34% |
| Week 4 | $6.79 | $8.58 | $10.85 | +3.13% |
| Week 5 | $6.65 | $8.65 | $11.24 | +3.93% |
| Week 6 | $6.54 | $8.71 | $11.61 | +4.74% |
| Week 7 | $6.44 | $8.78 | $11.97 | +5.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of chimeric antigen receptor cell therapy for light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Immix Biopharma, Inc. was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc. trades under the symbol IMMX. The current price is $8.17. Its market cap is $581.62M and it ranks 2910 in market capitalization. The overall price outlook remains constructive, with the forecast showing upside potential over time.
The forecast projects the average price rising from $8.17 in 2026 to $16.75 in 2030 and further to $88.50 by 2050, suggesting meaningful long-term upside despite intermediate volatility.
A major floor 32.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 44.5% above — a clean break opens room to run.
A major ceiling 60.5% above — clearing it would confirm fresh momentum.
Key IMMX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMMX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.43 | Sell | $8.49 | Sell |
| MA 10 | $8.73 | Sell | $8.82 | Sell |
| MA 20 | $9.75 | Sell | $9.22 | Sell |
| MA 50 | $9.30 | Sell | $9.37 | Sell |
| MA 100 | $9.42 | Sell | $8.92 | Sell |
| MA 200 | $7.40 | Buy | $7.61 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.97 | Neutral |
| Stoch RSI (14) | 12.99 | Buy |
| CCI (20) | -93.22 | Neutral |
| Williams %R (14) | -94.02 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | -20.99 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 5.98 | Buy |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -1.23 | Sell |
| Ultimate (7,14,28) | 29.45 | Buy |
| Momentum (10) | -1.93 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 8.21 | Buy |
| ADX (14) | 17.29 | Neutral |
| ATR (14) | 0.39 | Info |
The 30-day technical picture is bullish, with RSI14 at 40. The stock trades above a 200-day benchmark on a near-term basis, with SMA50 at $9.32 and SMA200 at $7.34. There is a defined near-term support at $8.17 and a resistance at $12.02.
The 30-day price range runs from a low of $6.04 to a high of $11.05, indicating a broad channel in which price action could move in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.44 | $8.32 | $12.65 | 0% | Neutral | |
| $10.41 | $13.83 | $19.76 | +66% | Bullish | |
| $12.04 | $16.80 | $25.38 | +102% | Bullish | |
| $11.74 | $17.08 | $26.93 | +105% | Bullish | |
| $12.17 | $18.37 | $30.01 | +121% | Bullish | |
| $13.27 | $20.73 | $34.92 | +149% | Bullish | |
| $14.53 | $23.44 | $40.60 | +182% | Bullish | |
| $19.71 | $32.79 | $58.19 | +294% | Bullish | |
| $21.34 | $36.56 | $66.34 | +339% | Bullish | |
| $21.30 | $37.56 | $69.57 | +351% | Bullish | |
| $32.54 | $65.70 | $132.50 | +690% | Bullish | |
| $50.47 | $112.16 | $255.14 | +12.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.44 | $8.32 | $10.18 | +0.00% |
| September 2026 | $7.39 | $8.90 | $11.14 | +6.99% |
| October 2026 | $7.55 | $9.20 | $11.71 | +3.35% |
| November 2026 | $7.40 | $9.10 | $11.74 | -1.09% |
| December 2026 | $7.81 | $9.69 | $12.65 | +6.48% |
Click any year to see its month-by-month IMMX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IMMX price prediction for 2026 points to an average of $8.32 (low $4.44, high $12.65) — a potential gain of 0% on today's $8.32. Price action looks broadly range-bound.
In 2027, IMMX is projected to trade between $10.41 and $19.76, averaging $13.83 — a potential gain of +66% from today's $8.32. That is up +66% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Immix Biopharma, Inc.'s 2028 outlook centres on $16.80, within a $12.04 to $25.38 range. That is up +21% on the projected 2027 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2029, IMMX could reach as high as $26.93, with a base case around $17.08 and support toward $11.74 — roughly +105% from $8.32. Buyers look set to stay in control over this stretch.
Expect IMMX to range from $12.17 to $30.01 through 2030. The $18.37 average target implies a +121% move from current prices. That is up +8% on the projected 2029 average. Momentum favours further upside here.
The IMMX price prediction for 2031 points to an average of $20.73 (low $13.27, high $34.92) — a potential gain of +149% on today's $8.32. Buyers look set to stay in control over this stretch.
In 2032, IMMX is projected to trade between $14.53 and $40.60, averaging $23.44 — a potential gain of +182% from today's $8.32. That is up +13% on the projected 2031 average. Momentum favours further upside here.
Immix Biopharma, Inc.'s 2033 outlook centres on $32.79, within a $19.71 to $58.19 range. That is up +40% on the projected 2032 average. That marks a +294% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IMMX could reach as high as $66.34, with a base case around $36.56 and support toward $21.34 — roughly +339% from $8.32. Momentum favours further upside here.
Expect IMMX to range from $21.30 to $69.57 through 2035. The $37.56 average target implies a +351% move from current prices. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IMMX price prediction for 2040 points to an average of $65.70 (low $32.54, high $132.50) — a potential gain of +690% on today's $8.32. Momentum favours further upside here.
In 2050, IMMX is projected to trade between $50.47 and $255.14, averaging $112.16 — a potential gain of +12.5x from today's $8.32. That is up +71% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMMX today (≈ 120.192308 IMMX) could be worth
$13,481.02
+$12,481.02 (+1248%) by 2050 · US Dollar
Based on the average projected IMMX price of $112.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMMXwould be worth at today's price.
$1,000 invested in IMMX on Jul 31, 2025 (≈ 367.647055 IMMX) would be worth
$3,058.82
+$2,058.82 (+205.9%) today · 3.06× · US Dollar
Based on a IMMX entry price of $2.72 vs. today's $8.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.52 | $976.53 | -2.3% |
| 1 month ago | $9.83 | $846.39 | -15.4% |
| 3 months ago | $9.3 | $894.62 | -10.5% |
| 6 months ago | $6.21 | $1,339.77 | +34.0% |
| 1 year ago | $2.72 | $3,058.82 | +205.9% |
| All time (4.6y) ago | $3.67 | $2,267.03 | +126.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMMX forecast.
Our base-case forecast reaches $17.00 around 2029.
Implied market cap at $17.00: $1.21B
Over the multi-year forecast, the average price is projected to move from $8.17 in 2026 to $16.75 in 2030 and to a higher $88.50 by 2050. The forecast shows bullish sentiment in 2027 onward, with the 2030 average at $16.75 and a 105% ROI, continuing to higher levels thereafter (2040 average $53.95 and 560.4% ROI; 2050 average $88.50 and 983.2% ROI).
The sequence of increasingly bullish forecasts suggests potential for substantial upside over the long term, though 2026 is listed as neutral. These numbers are estimates and may not reflect actual future results, which can be affected by a wide range of risks and uncertainties.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $16.75, with a minimum of $10.98 and a maximum of $27.65, and a forecasted ROI of 105%. The sentiment is BULLISH.
The forecast depicts a bullish sentiment in 2027 and beyond with notable upside potential, while 2026 is Neutral. These are estimates and not guarantees of future performance.
Yes—the forecast maximum for 2050 is $203.55, with an average of $88.50.
The current price is $8.17 and the market cap is $581.62M.
The 30-day range is from $6.04 to $11.05.
Immix Biopharma, Inc. Community Discussion
0Share your Immix Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.